Last reviewed · How we verify

NCT04958187

An Open Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of ANG-3777 Injected Intravenously in Stable Adult Maintenance Hemodialysis Subjects

Status unknown Phase 1 Last updated 9 July 2021
What this trial tests

Phase 1 trial testing ANG-3777 in Hemodialysis in 16 participants. Status unknown.

Timeline
1 July 2021
Primary endpoint
1 October 2021
1 October 2021

Quick facts

Lead sponsorAngion Biomedica Corp
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment16
Start date1 July 2021
Primary completion1 October 2021
Estimated completion1 October 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Angion Biomedica Corp — full company profile →

Who can join

Adults 18 to 75, any sex, with Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to evaluate the pharmacokinetics and safety of a single-dose of ANG-3777 in subjects with renal failure receiving maintenance hemodialysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hemodialysis

Currently open trials in the same condition.

Other Angion Biomedica Corp trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04958187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing